SARS-CoV-2 is associated with changes in brain structure in UK Biobank
Gwenaëlle Douaud, Soojin Lee, Fidel Alfaro-Almagro, Christoph Arthofer, Chaoyue Wang, Paul McCarthy, Frederik Lange, Jesper L R Andersson, Ludovica Griffanti, Eugene Duff, Saad Jbabdi, Bernd Taschler, Peter Keating, Anderson M Winkler, Rory Collins, Paul M Matthews, Naomi Allen, Karla L Miller, Thomas E Nichols, Stephen M Smith, Gwenaëlle Douaud, Soojin Lee, Fidel Alfaro-Almagro, Christoph Arthofer, Chaoyue Wang, Paul McCarthy, Frederik Lange, Jesper L R Andersson, Ludovica Griffanti, Eugene Duff, Saad Jbabdi, Bernd Taschler, Peter Keating, Anderson M Winkler, Rory Collins, Paul M Matthews, Naomi Allen, Karla L Miller, Thomas E Nichols, Stephen M Smith
Abstract
There is strong evidence of brain-related abnormalities in COVID-191-13. However, it remains unknown whether the impact of SARS-CoV-2 infection can be detected in milder cases, and whether this can reveal possible mechanisms contributing to brain pathology. Here we investigated brain changes in 785 participants of UK Biobank (aged 51-81 years) who were imaged twice using magnetic resonance imaging, including 401 cases who tested positive for infection with SARS-CoV-2 between their two scans-with 141 days on average separating their diagnosis and the second scan-as well as 384 controls. The availability of pre-infection imaging data reduces the likelihood of pre-existing risk factors being misinterpreted as disease effects. We identified significant longitudinal effects when comparing the two groups, including (1) a greater reduction in grey matter thickness and tissue contrast in the orbitofrontal cortex and parahippocampal gyrus; (2) greater changes in markers of tissue damage in regions that are functionally connected to the primary olfactory cortex; and (3) a greater reduction in global brain size in the SARS-CoV-2 cases. The participants who were infected with SARS-CoV-2 also showed on average a greater cognitive decline between the two time points. Importantly, these imaging and cognitive longitudinal effects were still observed after excluding the 15 patients who had been hospitalised. These mainly limbic brain imaging results may be the in vivo hallmarks of a degenerative spread of the disease through olfactory pathways, of neuroinflammatory events, or of the loss of sensory input due to anosmia. Whether this deleterious effect can be partially reversed, or whether these effects will persist in the long term, remains to be investigated with additional follow-up.
Conflict of interest statement
R.C. has been seconded from the University of Oxford as chief executive and principal investigator of UK Biobank, which is a charitable company. N.A. is chief scientist for UK Biobank. P.M.M. acknowledges consultancy fees from Novartis and Biogen; he has received recent honoraria or speakers’ honoraria and research or educational funds from Novartis, Bristol Myers Squibb and Biogen. P.M.M. serves as the honorary chair of the UK Biobank Imaging Working Group and as an unpaid member of the UK Biobank Steering Committee; he is chair of the UKRI Medical Research Council Neurosciences and Mental Health Board.
© 2022. The Author(s).
Figures
References
- Paterson RW, et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143:3104–3120.
- de Erausquin GA, et al. The chronic neuropsychiatric sequelae of COVID-19: the need for a prospective study of viral impact on brain functioning. Alzheimers Dement. 2021;17:1056–1065.
- Yang AC, et al. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021;595:565–571.
- Deleidi M, Isacson O. Viral and inflammatory triggers of neurodegenerative diseases. Sci. Transl. Med. 2012;4:121ps123.
- Butowt R, Meunier N, Bryche B, von Bartheld CS. The olfactory nerve is not a likely route to brain infection in COVID-19: a critical review of data from humans and animal models. Acta Neuropathol. 2021;141:809–822.
- Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–427.
- Taquet M, Luciano S, Geddes JR, Harrison PJ. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130–140.
- Helms J, et al. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 2020;382:2268–2270.
- Manca R, De Marco M, Ince P. G., Venneri A. Heterogeneity in regional damage detected by neuroimaging and neuropathological studies in older adults with COVID-19: a cognitive-neuroscience systematic review to inform the long-term impact of the virus on neurocognitive trajectories. Front. Aging Neurosci. 2021;13:646908.
- Mukerji SS, Solomon IH. What can we learn from brain autopsies in COVID-19? Neurosci. Lett. 2021;742:135528.
- Meinhardt J, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2021;24:168–175.
- Puelles VG, et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 2020;383:590–592.
- Matschke J, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet Neurol. 2020;19:919–929.
- Chertow, D. et al. SARS-CoV-2 infection and persistence throughout the human body and brain. Preprint at Research Square10.21203/-1139035/v1 (2021).
- Philippens, I. H. C. H. M. et al. SARS-CoV-2 causes brain inflammation and induces Lewy body formation in macaques. Preprint at bioRxiv10.1101/2021.02.23.432474 (2021).
- Lechien JR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur. Arch. Otorhinolaryngol. 2020;277:2251–2261.
- Cooper KW, et al. COVID-19 and the chemical senses: supporting players take center stage. Neuron. 2020;107:219–233.
- Hosp JA, et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. Brain. 2021;144:1263–1276.
- Postma EM, Smeets PAM, Boek WM, Boesveldt S. Investigating morphological changes in the brain in relation to etiology and duration of olfactory dysfunction with voxel-based morphometry. Sci. Rep. 2021;11:12704.
- Butowt R, Bilinska K. SARS-CoV-2: olfaction, brain infection, and the urgent need for clinical samples allowing earlier virus detection. ACS Chem. Neurosci. 2020;11:1200–1203.
- Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 2008;82:7264–7275.
- Brann DH, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci. Adv. 2020;6:eabc5801.
- Carmichael ST, Clugnet MC, Price JL. Central olfactory connections in the macaque monkey. J. Comp. Neurol. 1994;346:403–434.
- Palouzier-Paulignan B, et al. Olfaction under metabolic influences. Chem. Senses. 2012;37:769–797.
- Guedj E, et al. 18F-FDG brain PET hypometabolism in post-SARS-CoV-2 infection: substrate for persistent/delayed disorders? Eur. J. Nucl. Med. Mol. Imaging. 2021;48:592–595.
- Raman B, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021;31:100683.
- Griffanti L, et al. Adapting the UK Biobank brain imaging protocol and analysis pipeline for the C-MORE multi-organ study of COVID-19 survivors. Front. Neurol. 2021;12:753284.
- Reichert JL, Schopf V. Olfactory loss and regain: lessons for neuroplasticity. Neuroscientist. 2018;24:22–35.
- Han P, et al. Olfactory brain gray matter volume reduction in patients with chronic rhinosinusitis. Int. Forum Allergy Rhinol. 2017;7:551–556.
- Zhou G, Lane G, Cooper SL, Kahnt T, Zelano C. Characterizing functional pathways of the human olfactory system. eLife. 2019;8:e47177.
- Fraser MA, et al. Longitudinal trajectories of hippocampal volume in middle to older age community dwelling individuals. Neurobiol. Aging. 2021;97:97–105.
- Ronnlund M, Nyberg L, Backman L, Nilsson LG. Stability, growth, and decline in adult life span development of declarative memory: cross-sectional and longitudinal data from a population-based study. Psychol. Aging. 2005;20:3–18.
- Vidal-Pineiro D, et al. Individual variations in ‘brain age’ relate to early-life factors more than to longitudinal brain change. eLife. 2021;10:e69995.
- Diana RA, Yonelinas AP, Ranganath C. Imaging recollection and familiarity in the medial temporal lobe: a three-component model. Trends Cogn. Sci. 2007;11:379–386.
- Staresina BP, Duncan KD, Davachi L. Perirhinal and parahippocampal cortices differentially contribute to later recollection of object- and scene-related event details. J. Neurosci. 2011;31:8739–8747.
- Naya Y, Suzuki WA. Integrating what and when across the primate medial temporal lobe. Science. 2011;333:773–776.
- Doty RL. Olfaction: smell of change in the air. Cerebrum. 2017;2017:cer-10-17.
- Avery JA, et al. Taste quality representation in the human brain. J. Neurosci. 2020;40:1042–1052.
- Chikazoe J, Lee DH, Kriegeskorte N, Anderson AK. Distinct representations of basic taste qualities in human gustatory cortex. Nat. Commun. 2019;10:1048.
- Ferdon S, Murphy C. The cerebellum and olfaction in the aging brain: a functional magnetic resonance imaging study. Neuroimage. 2003;20:12–21.
- Kas A, et al. The cerebral network of COVID-19-related encephalopathy: a longitudinal voxel-based 18F-FDG-PET study. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:2543–2557.
- Qin Y, et al. Long-term microstructure and cerebral blood flow changes in patients recovered from COVID-19 without neurological manifestations. J. Clin. Invest. 2021;131:e147329.
- Tsai ST, Lu MK, San S, Tsai CH. The neurologic manifestations of coronavirus disease 2019 pandemic: a systemic review. Front. Neurol. 2020;11:498.
- Han P, Musch M, Abolmaali N, Hummel T. Improved odor identification ability and increased regional gray matter volume after olfactory training in patients with idiopathic olfactory loss. iPerception. 2021;12:20416695211005811.
- Blazhenets G, et al. Slow but evident recovery from neocortical dysfunction and cognitive impairment in a series of chronic COVID-19 patients. J. Nucl. Med. 2021;62:910–915.
- Douaud G, et al. DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer’s disease. Neuroimage. 2011;55:880–890.
- Douaud G, et al. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc. Natl Acad. Sci. USA. 2013;110:9523–9528.
- Fawns-Ritchie C, Deary IJ. Reliability and validity of the UK Biobank cognitive tests. PLoS ONE. 2020;15:e0231627.
- Mahlberg R, Adli M, Bschor T, Kienast T. Age effects on trail making test during acute depressive and manic episode. Int. J. Neurosci. 2008;118:1347–1356.
- Mahurin RK, et al. Trail making test errors and executive function in schizophrenia and depression. Clin. Neuropsychol. 2006;20:271–288.
- Ashendorf L, et al. Trail making test errors in normal aging, mild cognitive impairment, and dementia. Arch. Clin. Neuropsychol. 2008;23:129–137.
- Sobel N, et al. Odorant-induced and sniff-induced activation in the cerebellum of the human. J. Neurosci. 1998;18:8990–9001.
- Rowland MJ, et al. Early brain injury and cognitive impairment after aneurysmal subarachnoid haemorrhage. Sci. Rep. 2021;11:23245.
- Zhao S, et al. Rapid vigilance and episodic memory decrements in COVID-19 survivors. Brain Commun. 2022;4:fcab295.
- Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 2014;14:463–477.
- Deeks JJ, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst. Rev. 2020;6:CD013652.
- Salat DH, et al. Thinning of the cerebral cortex in aging. Cereb. Cortex. 2004;14:721–730.
- Zhao L, et al. Age-related differences in brain morphology and the modifiers in middle-aged and older adults. Cereb. Cortex. 2019;29:4169–4193.
- Elliott LT, et al. Genome-wide association studies of brain imaging phenotypes in UK Biobank. Nature. 2018;562:210–216.
- Miller KL, et al. Multimodal population brain imaging in the UK Biobank prospective epidemiological study. Nat. Neurosci. 2016;19:1523–1536.
- Alfaro-Almagro F, et al. Image processing and quality control for the first 10,000 brain imaging datasets from UK Biobank. Neuroimage. 2018;166:400–424.
- Littlejohns TJ, et al. The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions. Nat. Commun. 2020;11:2624.
- Smith SM, et al. An expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank. Nat. Neurosci. 2021;24:737–745.
- Wang, C. et al. Phenotypic and genetic associations of quantitative magnetic susceptibility in UK Biobank brain imaging. Preprint at bioRxiv10.1101/2021.06.28.450248 (2021).
- Pauli WM, Nili AN, Tyszka JM. A high-resolution probabilistic in vivo atlas of human subcortical brain nuclei. Sci. Data. 2018;5:180063.
- Griffanti L, et al. BIANCA (Brain Intensity AbNormality Classification Algorithm): a new tool for automated segmentation of white matter hyperintensities. Neuroimage. 2016;141:191–205.
- Wang C, et al. Methods for quantitative susceptibility and R2* mapping in whole post-mortem brains at 7T applied to amyotrophic lateral sclerosis. Neuroimage. 2020;222:117216.
- Iglesias JE, et al. A probabilistic atlas of the human thalamic nuclei combining ex vivo MRI and histology. Neuroimage. 2018;183:314–326.
- Iglesias JE, et al. Bayesian longitudinal segmentation of hippocampal substructures in brain MRI using subject-specific atlases. Neuroimage. 2016;141:542–555.
- Iglesias JE, et al. Bayesian segmentation of brainstem structures in MRI. Neuroimage. 2015;113:184–195.
- Saygin ZM, et al. High-resolution magnetic resonance imaging reveals nuclei of the human amygdala: manual segmentation to automatic atlas. Neuroimage. 2017;155:370–382.
- Neudorfer C, et al. A high-resolution in vivo magnetic resonance imaging atlas of the human hypothalamic region. Sci. Data. 2020;7:305.
- Alfaro-Almagro F, et al. Confound modelling in UK Biobank brain imaging. Neuroimage. 2021;224:117002.
- Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med. Res. Methodol. 2001;1:6.
- Papst I, et al. Age-dependence of healthcare interventions for COVID-19 in Ontario, Canada. BMC Public Health. 2021;21:706.
- Levin AT, et al. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol. 2020;35:1123–1138.
Source: PubMed